{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:16Z","timestamp":1772119156879,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06076-1","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:53:40Z","timestamp":1730804020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed\/ refractory patients with Waldenstr\u00f6m\u2019s macroglobulinemia"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-6463","authenticated-orcid":false,"given":"C\u00e9cile","family":"Tomowiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Nudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9r\u00e8se","family":"Aurran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Lepr\u00eatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souad","family":"Assaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Lhermitte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Torregrosa-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on the behalf of the FILO group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"2","key":"6076_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.seminhematol.2023.03.007","volume":"60","author":"R Garcia-Sanz","year":"2023","unstructured":"Garcia-Sanz R, Varettoni M, Jim\u00e9nez C, Ferrero S, Poulain S, San-Miguel JF, Guerrera ML, Drandi D, Bagratuni T, McMaster M, Roccaro AM, Roos-Weil D, Leiba M, Li Y, Qiu L, Hou J, De Larrea CF, Castillo JJ, Dimopoulos M, Owen RG, Treon SP, Hunter ZR (2023) Report of Consensus Panel 3 from the 11th International workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia: Recommendations for molecular diagnosis in Waldenstr\u00f6m\u2019s Macroglobulinemia. Semin Hematol 60(2):90\u201396","journal-title":"Semin Hematol"},{"issue":"11","key":"6076_CR2","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D\u2019Sa S et al (2020) Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia. Lancet Haematol 7(11):e827\u2013e837","journal-title":"Lancet Haematol"},{"issue":"1","key":"6076_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.21.01194","volume":"40","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C et al (2022) Venetoclax in Previously Treated Waldenstr\u00f6m Macroglobulinemia. J Clin Oncol 40(1):63\u201371","journal-title":"J Clin Oncol"},{"issue":"17","key":"6076_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1182\/blood.2021012953","volume":"138","author":"SP Treon","year":"2021","unstructured":"Treon SP, Meid K, Hunter ZR, Flynn CA, Sarosiek SR, Leventoff CR et al (2021) Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia. Blood 138(17):1535\u20131539","journal-title":"Blood"},{"issue":"Supplement 1","key":"6076_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1182\/blood-2021-144706","volume":"138","author":"SP Treon","year":"2021","unstructured":"Treon SP, Buske C, Thomas SK, Castillo JJ, Branagan AR, Dimopoulos MA et al (2021) Preliminary clinical response data from a phase 1b study of mavorixafor in combination with ibrutinib in patients with Waldenstrom\u2019s acroglobulinemia with MYD88 and CXCR4 mutations. Blood 138(Supplement 1):1362","journal-title":"Blood"},{"issue":"9","key":"6076_CR6","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","volume":"5","author":"C Tomowiak","year":"2021","unstructured":"Tomowiak C, Poulain S, Herbaux C, Perrot A, Mah\u00e9 B, Morel P et al (2021) Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia. Blood Adv 5(9):2438\u20132446","journal-title":"Blood Adv"},{"issue":"2","key":"6076_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G et al (2013) VIth International Workshop on Waldenstr\u00f6m macroglobulinaemia. Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 160(2):171\u20136","journal-title":"Br J Haematol."},{"issue":"6","key":"6076_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1200\/JCO.20.00555","volume":"39","author":"SP Treon","year":"2021","unstructured":"Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X et al (2021) Long-Term Follow-Up Ibrutinib\u00a0Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 39(6):565\u2013575","journal-title":"J Clin Oncol."},{"issue":"2","key":"6076_CR9","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","volume":"7","author":"RG Owen","year":"2020","unstructured":"Owen RG, McCarthy H, Rule S, D\u2019Sa S, Thomas SK, Tournilhac O et al (2020) Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 7(2):e112\u2013e121","journal-title":"Lancet Haematol"},{"issue":"33","key":"6076_CR10","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G et al (2023) Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol 41(33):5099\u20135510","journal-title":"J Clin Oncol"},{"issue":"5","key":"6076_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/joim.12600","volume":"282","author":"M Jerkeman","year":"2017","unstructured":"Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L (2017) Targeting of B-cell\u00a0receptor signalling in B-cell\u00a0malignancies. J Intern Med. 282(5):415\u2013428","journal-title":"J Intern Med."},{"key":"6076_CR12","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","volume":"103","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP (2018) Ibrutinib withdrawal symptoms in patients with Waldenstr\u00f6m macroglobulinemia. Haematologica. 103:e307\u2013e310","journal-title":"Haematologica."},{"issue":"22","key":"6076_CR13","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S et al (2022) Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139(22):3278\u20133289","journal-title":"Blood"},{"issue":"7","key":"6076_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood.2023022420","volume":"143","author":"JJ Castillo","year":"2024","unstructured":"Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M et al (2024) Ibrutinib\u00a0and\u00a0venetoclax\u00a0as primary therapy in symptomatic, treatment-naive\u00a0Waldenstrom\u00a0macroglobulinemia. Blood 143(7):582\u2013591","journal-title":"Blood"},{"issue":"7","key":"6076_CR15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","volume":"8","author":"CS Tam","year":"2024","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G et al (2024) Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom macroglobulinemia. Blood Adv 8(7):1639\u20131650","journal-title":"Blood Adv"},{"issue":"20","key":"6076_CR16","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","volume":"23","author":"S Poulain","year":"2017","unstructured":"Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E et al (2017) TP53 mutation and its prognostic significance in Waldenstrom\u2019s macroglobulinemia. Clin Cancer Res. 23(20):6325\u20136335","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06076-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06076-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06076-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:54:40Z","timestamp":1730804080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06076-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":16,"alternative-id":["6076"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06076-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4978701\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and amendments laid down by the 29th (Tokyo, 1975), the 35th (Venice, 1983) and the 41st (Hong Kong, 1989), the 48th (Somerset West, 1996), the 52nd ( Edinburg, 2000) World Medical Assemblies, the 64th (Fortazela, 2013) notes for clarification added by the WMA General Assembly on paragraph 29 (Washington 2002) and on Paragraph 30 (Tokyo 2004) and amendment laid down by the 59th (Seoul, October 2008) World Medical Assemblies.The trial was approved by the following competent authorities: health autority (ANSM) autorisation date: August 25, 2016 and ethics comittee (CPP OUEST III): August 31, 2016.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}